MoonLake Immunotherapeutics
MLTX
$39.65
$0.982.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -513.20% | -275.45% | -139.34% | -51.85% | 56.53% |
| Total Depreciation and Amortization | 261.07% | 884.85% | 751.52% | 590.91% | 10,821.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -123.41% | 325.32% | 330.69% | 379.90% | -67.45% |
| Change in Net Operating Assets | 39.24% | 752.83% | -309.64% | -636.96% | -425.97% |
| Cash from Operations | -292.68% | -173.22% | -129.38% | -65.64% | -6.45% |
| Capital Expenditure | 38.30% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -225.61% | 133.50% | -792.19% | -245.52% | 1,083.18% |
| Cash from Investing | -226.07% | 133.42% | -792.19% | -246.60% | 1,080.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.52% | -- | -100.00% | -- | 820,144.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -99.47% | -- | -100.00% | -- | 747,700.00% |
| Foreign Exchange rate Adjustments | 555.02% | -6,608.00% | 88.30% | 9,400.00% | 879.52% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -246.79% | 117.90% | -125.61% | -31.55% | 7,928.34% |
